SCHEMBL30587241

SCHEMBL30587241

CSc1cc(OS(=O)(=O)C(F)(F)F)c2c3c(c(-c4ccc(F)c5sc(NC(=O)OC(C)(C)C)c(C#N)c45)c(Cl)c2n1)COC3

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26118481 1.00
SCHEMBL31278379 1.00
SCHEMBL26114998 0.90 THRB (0.31)
SCHEMBL30587224 0.90 THRB (0.31)
SCHEMBL33526107 0.89 EIF4EBP1 (0.31)
SCHEMBL31278508 0.89 THRB (0.31)
SCHEMBL30587198 0.89 THRB (0.31)
SCHEMBL26115041 0.89 THRB (0.31)
SCHEMBL26114057 0.86
SCHEMBL30587288 0.86 KDM4E (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4499233-A1 KRAS INHIBITORS Eli Lilly and Company (US) 2025-02-05 EP disclosed
WO-2023183585-A1 KRAS INHIBITORS ELI LILLY AND COMPANY (US) 2023-09-28 WO disclosed